How much funding has Adamas Pharmaceuticals raised?

Adamas Pharmaceuticals has raised $40.0M in total funding, most recently a Series D round.

Who are Adamas Pharmaceuticals's investors?

Adamas Pharmaceuticals's investors include Aeris Capital, DAG Ventures, Mohr Davidow Ventures, Northgate Capital.

When was Adamas Pharmaceuticals founded?

Adamas Pharmaceuticals was founded in 2000.

Where is Adamas Pharmaceuticals headquartered?

Adamas Pharmaceuticals is headquartered in Emeryville, California, United States.

What industry is Adamas Pharmaceuticals in?

Adamas Pharmaceuticals operates in Biotech, Healthcare.

How many employees does Adamas Pharmaceuticals have?

Adamas Pharmaceuticals has 51-200 employees.

Adamas Pharmaceuticals

Emeryville, United States · Founded 2000 · $40.0M raised

Biotech

Healthcare

Headquarters: Emeryville, California
Employees: 51–200
Founded: 2000
Business Model: B2B

Website: adamaspharma.com
Total Funding: $40.0M
Last Round: $40.0M Series DAug 2009
Rounds: 2

About

Adamas Pharmaceuticals was a specialty pharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) and neurological diseases. The company specialized in controlled-release combination therapeutics targeting conditions such as Parkinson's disease, multiple sclerosis, and other chronic CNS disorders. Adamas was headquartered in Emeryville, California, and traded on NASDAQ under the ticker ADMS. The company's mission was to improve the lives of patients suffering from CNS diseases through innovative treatments driven by integrity, commitment, and scientific innovation. In November 2021, Adamas was acquired by Supernus Pharmaceuticals for approximately $450 million, with its pipeline and products integrated into Supernus's broader CNS portfolio.

Summary

Adamas Pharmaceuticals is a Biotech company based in Emeryville, United States, founded in 2000. It has raised $40.0M in total across 2 rounds, most recently a $40.0M Series D round in Aug 2009. Investors include Aeris Capital, DAG Ventures and Mohr Davidow Ventures.